GP Matters - Weight-loss Clinic in Glasgow
The Wegovy Pill is not yet available to buy in the UK,
It is currently awaiting regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA).
Send us an email to receive updates about the Wegovy Pill availability at GP Matters.
Wake up, then Wegovy®
The proven weight-loss benefits of Wegovy® are now available (USA only) in the once-daily Wegovy® pill. See how this option can help adults lose weight and keep it off.
Take one every morning.
Your healthcare professional will initiate treatment with the 1.5 mg once-daily dose and will increase the dose every 30 days, as tolerated, until the 25 mg maximum is reached. Gradual dose escalation helps your body adjust to the medication.
Your healthcare professional will initiate treatment with the 1.5 mg once-daily dose and will increase the dose every 30 days, as tolerated, until the 25 mg maximum is reached. Gradual dose escalation helps your body adjust to the medication.
The active ingredient in the Wegovy pill is semaglutide, a GLP-1 receptor agonist. GLP-1 is a hormone your body releases after eating that helps regulate appetite and manage blood sugar levels.
By mimicking the GLP-1 hormone, the Wegovy pill causes weight loss by:
Reducing appetite and food cravings, helping you feel satiated with smaller portions of food.
Slowing gastric emptying (the rate at which food leaves the stomach), which helps you feel fuller for longer after meals.
Regulating blood sugar by increasing insulin secretion when glucose levels are high, preventing blood sugar spikes and food cravings.
In the Phase 3 OASIS-4 clinical trial, individuals taking 25mg of oral semaglutide daily for 64 weeks lost an average of 16.6% of their body weight. Around one in three participants also achieved 20% or more of body weight loss.
As well as body weight reduction, clinical trial findings also suggest improvements in health metrics commonly linked to being obese or overweight, such as blood sugar control and other markers associated with cardiovascular and metabolic health.
As with any weight management treatment, the weight loss results can vary based on starting weight, dose escalation, consistency with daily dosing, lifestyle changes and how well the medication is tolerated.
Take your Wegovy® pill on an empty stomach in the morning with water (up to 4 ounces). Wait at least 30 minutes after taking before having any food, drinking beverages, or taking other oral medications. It is also important that the pill be swallowed whole.
The Wegovy pill and Wegovy injection both contain semaglutide and work by activating GLP-1 receptors that help reduce appetite and increase feelings of fullness. However, there are differences in dosing, absorption and average weight-loss outcomes.
The Wegovy pill is a once-daily oral tablet, while the Wegovy injection is taken once weekly. Where injectable semaglutide is absorbed more consistently, clinical trials have shown that Wegovy injections generally lead to slightly greater average weight loss compared with oral semaglutide.
In studies, the Wegovy pill(oral semaglutide 25 mg) has been shown to produce average weight loss of around 16-17% over 64 weeks. Wegovy injections have demonstrated average weight loss of around 15-17%, with some patients achieving higher reductions depending on dose and duration of treatment.
The Wegovy pill offers a needle-free alternative and may suit those who prefer oral medication, while the injection provides the convenience of once-weekly dosing and more predictable absorption. Suitability depends on individual preference, response to treatment and clinical assessment.
The Wegovy pill is not yet available to buy in the UK, as it is currently awaiting regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA).
You can sign up to be notified to receive updates as soon as the Wegovy pill becomes available in the UK market.
Register your interest - Wegovy® Oral Pill
In the UK, the Wegovy pill, also known as oral semaglutide, is currently under review by the Medicines and Healthcare products Regulatory Agency (MHRA) and other regulatory authorities as a prescription weight-loss treatment, with a decision expected later in 2026.
Novo Nordisk launched the Wegovy pill in the United States on 5 January 2026, following FDA approval as the first oral GLP-1 weight-loss medication. The Wegovy pill is available to eligible US patients as a once-daily alternative to GLP-1 injections. Subject to regulatory approval, the Wegovy pill may become available in the UK following completion of the MHRA review process.
If you miss a daily dose of Wegovy® pill, skip that day’s dose and get back on track by taking the scheduled dose the next day.
People respond to medication, including Wegovy®, differently, so there is no set time when you can expect to see results with Wegovy®. Ask your healthcare professional about what might be realistic for you.
In a medical study, adults living with obesity, or with overweight and at least one weight-related medical problem, who took Wegovy® pill, along with a reduced-calorie diet and increased physical activity, lost on average about 33 lb, which was about 14% of their starting body weight. In comparison, adults who took placebo lost on average about 6 lb, or about 2.4% of their starting body weight. The average starting weights were 235 lb and 231 lb for the Wegovy® and placebo groups, respectively.
76% or about 8 in 10 adults achieved 5% or more weight loss with Wegovy® compared with 31% taking placebo.
Results are from a 64-week medical study of 307 adults with obesity (BMI ≥30 kg/m2), or with overweight (BMI ≥27 kg/m2) and at least one weight-related medical problems, including high blood pressure or high cholesterol. Adults with type 2 diabetes were excluded. Patients were taking either Wegovy® pill or placebo. During the trial, 18% of adults in the Wegovy® group discontinued treatment compared with 26% of adults in the placebo group.
BMI=body mass index.
While everyone’s response to treatment will be different, in the medical study, people who took Wegovy® pill lost on average about 14% of their starting weight. Use the weight loss calculator to get an idea of how much weight you could lose with Wegovy®.
In the medical study, adults living with obesity, or with overweight and with at least one weight-related medical problem, who took Wegovy® pill, along with a reduced-calorie diet and increased physical activity, lost on average about 33 lb which was about 14% of their starting body weight. In comparison, adults who took placebo lost on average about 6 lb, or about 2.4% of their body weight. The average starting weights were 235 lb and 231 lb for the Wegovy® pill and placebo groups, respectively.
76% or about 8 in 10 adults achieved 5% or more weight loss with Wegovy® compared with 31% taking placebo.
Results are from a 64-week medical study of 307 adults with obesity (BMI ≥30 kg/m2) or with overweight (BMI ≥27 kg/m2) and at least one weight-related medical problems, including high blood pressure or high cholesterol. Adults with type 2 diabetes were excluded. Patients were taking either Wegovy® or placebo. During the trial, 18% of adults in the Wegovy® group discontinued treatment compared with 26% of adults in the placebo group.
The most common side effects of Wegovy® may include nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat. Tell your healthcare professional if you have any side effects that bother you or do not go away.